GlassScriptPhysician profile
Peter J Breingan
NPI 1770568560
$5,518.29
in general payments reported to CMS, 2019-2025
27 companies · $956 in 2025
The $956 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $129 · 2021: $577 · 2022: $1,206 · 2023: $564 · 2024: $1,395 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,897 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,896.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $855.27 | 2022-2025 | Durysta |
| Alcon Vision LLC | $826.60 | 2022-2025 | Clareon, Simbrinza, Eysuvis |
| Oyster Point Pharma, INC. | $605.27 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $566.84 | 2019-2023 | |
| New World Medical,INC. | $319.90 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $304.74 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $289.73 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $243.00 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.11 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $217.33 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $141.15 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $126.09 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $103.80 | 2022-2025 | Iyuzeh |
| Allergan, INC. | $93.61 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $91.37 | 2019-2023 | Tecnis Iol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $78.78 | 2019-2023 | Flarex |
| Amgen INC. | $73.87 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $63.36 | 2022 | |
| Rxsight INC | $53.61 | 2023 | Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $52.25 | 2019-2021 | |
| Shire North American Group INC | $44.91 | 2019 | |
| Rayner Intraocular Lenses Limited | $33.44 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Biotissue Holdings INC. | $25.06 | 2023 | |
| Eyepoint US, INC. | $23.66 | 2021 | |
| Astellas Pharma US INC | $19.18 | 2024 | Izervay |
| Carl Zeiss Meditec Cataract Technology INC. | $18.08 | 2020 | |
| Sight Sciences, INC. | $16.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Breingan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.